Crossmark

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Crossref DOI link: https://doi.org/10.1038/s41571-019-0182-8

Published Online: 2019-03-01

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Creelan, Benjamin C.

Antonia, Scott J.
License Information

Text and Data Mining valid from 2019-03-01
More Information

Article History

First Online: 1 March 2019

Competing interests

: B.C.C. is on the speaker’s bureau for AstraZeneca, Bristol–Myers Squibb, Foundation Medicine, Hoffman–LaRoche and Takeda, on the advisory board for AbbVie, Bristol–Myers Squibb, Celgene and GlaxoSmithKline, and receives funding from Boehringer-Ingelheim, Iovance Biotherapeutics and Prometheus. S.A.A. has served on the scientific advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol–Myers Squibb, Cellular Biomedicine Group, FLX Bio, Memgen, Merck, Nektar Therapeutics, Novartis and Venn Therapeutics.